15–22% Body Weight Loss Best Seller

Tirzepatide (Mounjaro® / Zepbound®)

Tirzepatide is a dual GIP / GLP-1 receptor agonist — a next-generation weight-loss medication. In SURMOUNT clinical trials it produced average weight loss of 20.9% at the highest dose, surpassing every prior medication and approaching bariatric-surgery outcomes.

How it works

The mechanism

By activating both GIP and GLP-1 receptors, tirzepatide produces stronger appetite suppression, better insulin sensitization and more efficient fat oxidation than single-agonist medications. The dual mechanism is also unusually effective at improving metabolic markers (A1c, triglycerides, blood pressure).

Who it's for

Best candidates

  • Men with substantial weight to lose (>15% of body weight)
  • Patients with type 2 diabetes or significant insulin resistance
  • Men who tried semaglutide and want a stronger result

Protocol

Once-weekly subcutaneous injection. Start 2.5 mg, titrate every 4 weeks: 5 → 7.5 → 10 → 12.5 → 15 mg. Most men hit their target dose by month 4–5.

Timeline

Appetite suppression and weight loss begin in week 1. Steady 1.5–2.5% body-weight loss per month at therapeutic doses.

What to expect

Side effects & considerations

Similar to semaglutide — nausea, constipation, GI changes. Generally well tolerated with slow titration.

Frequently asked

Tirzepatide (Mounjaro® / Zepbound®) FAQs

Pairs well with

Related treatments

Take the first step

Feel like yourself again — book a free consult.

15 minutes. No pressure. A clear plan if you want one.